Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision Radionuclide Therapy™
https://t.co/WsVKVWXhGY
Big news! Our cutting-edge cancer treatment is making headlines — thanks to our feature on CBS News Philadelphia. Watch how we’re delivering targeted radiation directly into tumors for pets and redefining veterinary oncology: https://t.co/a2NLpqq5P2
@saylor_monty Absolutely, there will be a lot of money for them to make over there as its rolled out. I'd just like to see them start saving human lives here in the US. I've been in this stock a long time, so the current price action doesn't bother me. I know what we have and what it could do.
Why is @US_FDA forcing so many companies to go overseas for trials? Shouldn’t the innovation stay in the USA? @RobertKennedyJr@DrMakaryFDA@MayoClinic is ready to start @RadioGel trials, but the FDA does not support innovation. Change Is needed. $RDGL
https://t.co/7zhvwCIfyn
Here is the latest update from yesterday’s meeting with the FDA. As stated our ultimate goal is to expand @RadioGel to treat humans both within the USA and abroad. Vivos Inc. is changing the way cancer is treated in humans and animals @IsoPetForCancer $RDGL
Update on the India Trials - Thursday, Feb 13 in Bangalore, India patients were treated using RadioGel® Precision Radionuclide Therapy™. We will update with more details as they become available. Subscribe to our email list at https://t.co/tgqyQwBh65 $RDGL